Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 31;27(1):54.
doi: 10.1186/s10020-021-00317-z.

Heterologous vaccine interventions: boosting immunity against future pandemics

Daniela Marín-Hernández  1 , Douglas F Nixon  2 , Nathaniel Hupert  3   4
Affiliations
Review

Heterologous vaccine interventions: boosting immunity against future pandemics

Daniela Marín-Hernández et al. Mol Med. .

Abstract

While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens. The best-known non-specific effects from an unrelated or heterologous vaccine are from the use of the Bacillus Calmette-Guérin (BCG) vaccine, mediated partly through trained immunity. Other vaccines have similar heterologous effects. This review covers molecular mechanisms behind the heterologous effects, and the potential use of heterologous vaccination in the current COVID-19 pandemic. We then discuss novel pandemic response strategies based on rapidly deployed, widespread heterologous vaccination to boost population-level immunity for initial, partial protection against infection and/or clinical disease, while specific vaccines are developed.

Keywords: BCG; Heterologous; Influenza vaccine; Innate immunity; Non-specific immunity; Trained immunity; Vaccination; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infection. 2019 doi: 10.1016/j.cmi.2019.08.011. - DOI - PubMed
    1. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from guinea-bissau. J Infect. 1984;8(1):13–21. doi: 10.1016/S0163-4453(84)93192-X. - DOI - PubMed
    1. Aaby P, Martins CL, Garly ML, Balé C, Andersen A, Rodrigues A, Ravn H, Lisse IM, Benn CS, Whittle HC. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ (online) 2010;341(7785):1262. doi: 10.1136/bmj.c6495. - DOI - PMC - PubMed
    1. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, Benn CS, Jensen H. Oral polio vaccination and low case fatality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine. 2004;22(23):3014–3017. doi: 10.1016/j.vaccine.2004.02.009. - DOI - PubMed
    1. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245–252. doi: 10.1093/infdis/jir240. - DOI - PubMed